Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic hMSCs in mild to moderate Alzheimer's dementia
NCT02833792Phase 2Unknown
- Sponsor
- Stemedica Cell Technologies
- Start
- Jun 2016
- Primary completion
- Jul 2024
- Modality
- Mesenchymal Stem Cells
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of ischemia-tolerant mesenchymal stem cells in Alzheimer's disease (AD) (2 arms), sponsored by Stemedica Cell Technologies. Primary endpoint: Safety of aMBMC administration at 18 months. Status: unknown.
02
Drugs
ischemia-tolerant mesenchymal stem cells
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02833792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02833792.